Logan Health is proud to announce the addition of PLUVICTO, a groundbreaking targeted treatment for prostate cancer, now available at Logan Health Medical Center. Logan Health becomes only the third health system in Montana to offer this innovative therapy, joining facilities in Helena and Billings.
Unlike traditional chemotherapy, which affects the entire body, PLUVICTO is a targeted treatment designed to attack prostate cancer cells directly. This means patients often experience fewer side effects and generally feel less sick compared to systemic chemotherapy. The therapy is also quick and convenient, administered through a short intravenous infusion in a comfortable outpatient setting.
Patients typically undergo six doses of PLUVICTO, scheduled once every six weeks. Candidacy for the treatment is determined by a patient’s referring physician or oncologist, who evaluates whether PLUVICTO is appropriate at a given point in the treatment journey. In some cases, it may even be recommended before chemotherapy.
The PLUVICTO treatment is administered at the Logan Health Medical Center Infusion Center, where patients receive the therapy intravenously in a supportive care setting. Logan Health’s cancer and nuclear medicine teams successfully administered the first PLUVICTO treatment in September, marking an important milestone in expanding cancer care options for patients in northwest Montana.
This treatment is authorized by Logan Health Radiation Oncologists Jeffrey Eshleman, MD, and Justin Linam, MD, in collaboration with the Logan Health Nuclear Medicine program.
“As we recognize September as Prostate Cancer Awareness Month, our teams are especially proud to bring this advanced treatment close to home,” said Dr. Linam. “PLUVICTO gives patients access to a more targeted, less invasive therapy while allowing them to stay near their support systems without traveling long distances for the latest innovations in cancer care.”
For more information about cancer services at Logan Health, visit logan.org/cancercare.
